Lipopolysaccharide cross-tolerance delays platelet-activating factor-induced sudden death in Swiss albino mice: Involvement of cyclooxygenase in cross-tolerance

12Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Lipopolysaccharide (LPS) signaling through Toll-like receptor-4 (TLR-4) has been implicated in the pathogenesis of many infectious diseases. Some believe that TLR-mediated pathogenicity is due, in part, to the lipid pro-inflammatory mediator platelet-activating factor (PAF), but this has been questioned. To test the direct contribution of PAF in endotoxemia in murine models, we injected PAF intraperitoneally into Swiss albino mice in the presence and absence of LPS. PAF alone (5 ìg/mouse) caused death within 15-20 min, but this could be prevented by pretreating mice with PAF-receptor (PAF-R) antagonists or PAFacetylhydrolase (PAF-AH). A low dose of LPS (5 mg/kg body wt) did not impair PAFinduced death, whereas higher doses (10 or 20 mg/kg body wt) delayed death, probably via LPS cross-tolerance. Cross-tolerance occurred only when PAF was injected simultaneously with LPS or within 30 min of LPS injection. Tolerance does not appear to be due to an abundant soluble mediator. Histologic examination of lungs and liver and measurement of circulating TNF-α and IL-10 levels suggested that the inflammatory response is not diminished during cross-tolerance. Interestingly, aspirin, a non-specific cyclooxygenase (COX) inhibitor, partially blocked PAF-induced sudden death, whereas NS-398, a specific COX-2 inhibitor, completely protected mice from the lethal effects of PAF. Both COX inhibitors (at 20 mg/kg body wt) independently amplified the cross-tolerance exerted by higher dose of LPS, suggesting that COX-derived eicosanoids may be involved in these events. Thus, PAF does not seem to have a protective role in endotoxemia, but its effects are delayed by LPS in a COX-sensitive way. These findings are likely to shed light on basic aspects of the endotoxin cross-tolerance occurring in many disease conditions and may offer new opportunities for clinical intervention.

Cite

CITATION STYLE

APA

Jacob, S. P., Lakshmikanth, C. L., Chaithra, V. H., Kumari, T. R. S., Chen, C. H., McIntyre, T. M., & Marathe, G. K. (2016). Lipopolysaccharide cross-tolerance delays platelet-activating factor-induced sudden death in Swiss albino mice: Involvement of cyclooxygenase in cross-tolerance. PLoS ONE, 11(4). https://doi.org/10.1371/journal.pone.0153282

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free